Condition: NSCLC (Non-small Cell Lung Carcinoma) · Stage III · EGFR Uncommon Mutations · Sponsor: Hunan Cancer Hospital
This is a prospective, single-arm, Phase II clinical study aimed at evaluating the efficacy and safety of 160mg fimonertinib in combination with definitive radiotherapy for patients with EGFR uncommon driver mutation-positive, Stage III unresectable lung adenocarcinoma. The primary endpoint is Progression-Free Survival (PFS), assessed by the investigator according to RECIST 1.1 criteria, defined as the time from the first dose to objective disease progression or death (from any cause). Secondary endpoints include PFS by different mutation types, OS, ORR, DCR, as well as adverse events and their severity.
This description comes directly from the study's public registry record.
Huai Liu · 0731-89762321 · liuhuai@hnca.org.cn
Xingxiang Pu · 0731-89762300 · puxingxiang@hnca.org.cn
Always discuss trial participation with your own doctor first.
| Hunan Cancer Hospital | Changsha, Hunan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07314216